Abstract: This invention relates to Activity Dependent Neurotrophic Factor I complex (ADNF I complex) and polypeptides of this complex, which produce their neurotrophic effects through multiple proteases intrinsic to the ADNF I complex. The invention also relates to pharmaceutical compositions comprising ADNF I complex polypeptides, as well as methods for reducing neuronal cell death in vitro and in vivo, methods for treating oxidative stress in a patient, methods for reducing a condition associated with fetal alcohol syndrome in a subject, and methods of enhancing learning and memory both pre- and post-natally, all of which methods use the ADNF I complex polypeptides of the invention.

Abstract: Methods for inhibiting cancer, scar formation, disrupting the cellular cytoskeleton, and conferring resistance from infection are disclosed. Such methods comprise the administration of oleuropein and/or the products of its hydrolysis in therapeutically effective amounts. To that end, a variety of pharmaceutical formulations and routes or administration are disclosed and may be utilized to treat a wide variety of diseases.

Abstract: This invention relates to Activity Dependent Neurotrophic Factor I complex (ADNF I complex) and polypeptides of this complex, which produce their neurotrophic effects through multiple proteases intrinsic to the ADNF I complex. The invention also relates to pharmaceutical compositions comprising ADNF I complex polypeptides, as well as methods for reducing neuronal cell death in vitro and in vivo, methods for treating oxidative stress in a patient, methods for reducing a condition associated with fetal alcohol syndrome in a subject, and methods of enhancing learning and memory both pre- and post-natally, all of which methods use the ADNF I complex polypeptides of the invention.

Abstract: In vitro methods are disclosed that rely on a novel phenomenon of secondary sprouting by cultured endothelial precursor cells, after angiogenic-like tube formation and collapse have occurred on a basement membrane matrix. Particularly disclosed is an in vitro method of isolating and expanding, from a mixed population of mammalian cells originating from a tissue sample, a cellular population enriched for endothelial sprout cells, including cells having one or more physiological and/or immunological features of endothelial precursor cells. Also disclosed is an in vitro method for a screening a substance for potential proangiogenic or antiangiogenic activity.

Abstract: This invention relates to Activity Dependent Neurotrophic Factor I complex (ADNF I complex) and polypeptides of this complex, which produce their neurotrophic effects through multiple proteases intrinsic to the ADNF I complex. The invention also relates to pharmaceutical compositions comprising ADNF I complex polypeptides, as well as methods for reducing neuronal cell death in vitro and in vivo, methods for treating oxidative stress in a patient, methods for reducing a condition associated with fetal alcohol syndrome in a subject, and methods of enhancing learning and memory both pre- and post-natally, all of which methods use the ADNF I complex polypeptides of the invention.

Abstract: In vitro methods are disclosed that rely on a novel phenomenon of secondary sprouting by cultured endothelial precursor cells, after angiogenic-like tube formation and collapse have occurred on a basement membrane matrix. Particularly disclosed is an in vitro method of isolating and expanding, from a mixed population of mammalian cells originating from a tissue sample, a cellular population enriched for endothelial sprout cells, including cells having one or more physiological and/or immunological features of endothelial precursor cells. Also disclosed is an in vitro method for a screening a substance for potential proangiogenic or antiangiogenic activity.

Abstract: A method of inhibiting angiogenesis in a mammal is disclosed, which employs a pharmaceutically acceptable composition containing a selective inhibitor of protein kinase CK2 (also known as casein kinase II) enzymatic activity, such as emodin, aloe-emodin, 5,6-dichloro-1-&bgr;-D-ribofuranosylbenzimidazole (DRB), and 4,5,6,7-tetrabromobenzotriazole (TBB). Also disclosed is a use of a selective inhibitor of protein kinase CK2 enzymatic activity in the manufacture of a medicament for inhibiting angiogenesis. An in vitro method of screening a potential antiangiogenic agent is also disclosed. A kit for the treatment of a disease by inhibiting angiogenesis is disclosed that contains the pharmaceutically acceptable composition containing a selective inhibitor of protein kinase CK2 enzymatic activity.

Abstract: Methods for inhibiting cancer, scar formation, disrupting the cellular cytoskeleton, and conferring resistance from infection are disclosed. Such methods comprise the administration of oleuropein and/or the products of its hydrolysis in therapeutically effective amounts. To that end, a variety of pharmaceutical formulations and routes or administration are disclosed and may be utilized to treat a wide variety of diseases.

Abstract: Methods for inhibiting angiogensis are disclosed the comprise administering oleouropein and/or the products of its hydrolysis in therapeutically effective amounts. The methods and compositions of the present invention are particularly effective in inhibiting the vascularization of endothelial cells, and may be utilized to treat a wide variety of cancers, ocular diseases, and inflammatory conditions.

Abstract: Methods for inhibiting angiogenisis are disclosed the comprise administering oleouropein and/or the products of its hydrolysis in therapeutically effective amounts. The methods and compositions of the present invention are particularly effective in inhibiting the vascularization of endothelial cells, and may be utilized to treat a wide variety of cancers, ocular diseases, and inflammatory conditions.

Abstract: Methods for inhibiting angiogensis are disclosed the comprise administering oleouropein and/or the products of its hydrolysis in therapeutically effective amounts. The methods and compositions of the present invention are particularly effective in inhibiting the vascularization of endothelial cells, and may be utilized to treat a wide variety of cancers, ocular diseases, and inflammatory conditions.